14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
GAB vs GRX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
GRX Captures Overall Composite Edge (41.3 SELL vs 45.7 HOLD), While GAB Leads 1–0 on Growth & Valuation Pillars
GRX Overall Winner
6-Pillar Tally: GAB 1 – 0 GRX (5 Tie)
Matrix Metrics: GAB 2 – 2 GRX
As of Nov 16, 2026, The Gabelli Healthcare & Wellness Trust (GRX) captures the overall head-to-head institutional edge over The Gabelli Equity Trust Inc. (GAB) on higher Unified Composite conviction (41.3/100 SELL vs. 45.7/100 HOLD) after splitting the core matrix 2–2 (led by composite factor balance), while GAB wins 1–0 across the 6-pillar growth and valuation breakdown. GAB trades at $5.27 (N/M Forward P/E, N/A operating margin) versus GRX at $10.58 (N/M Forward P/E, N/A operating margin).
Composite vs. Pillar Nuance: While GAB currently prints a higher short-term Unified Composite Score (45.7/100 HOLD vs. GRX 41.3/100 SELL), GRX captures the overall institutional head-to-head verdict (2–2 matrix metrics and 0–1 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY).
Technical & Structure Timing Caution: GAB is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.8); meanwhile GRX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GAB vs GRX. Trailing 12-month operating profitability (GAB N/A vs GRX N/A) and valuation multiples (GAB N/M vs GRX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with $142.9M market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ GAB vs GRX Key Questions & Quantitative Answers
As of Nov 16, 2026, The Gabelli Healthcare & Wellness Trust (GRX) captures the overall head-to-head institutional edge over The Gabelli Equity Trust Inc. (GAB) on higher Unified Composite conviction (41.3/100 SELL vs. 45.7/100 HOLD) after splitting the core matrix 2–2 (led by composite factor balance), while GAB wins 1–0 across the 6-pillar growth and valuation breakdown. GAB trades at $5.27 (N/M Forward P/E, N/A operating margin) versus GRX at $10.58 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While GAB currently prints a higher short-term Unified Composite Score (45.7/100 HOLD vs. GRX 41.3/100 SELL), GRX captures the overall institutional head-to-head verdict (2–2 matrix metrics and 0–1 across the 6 pillars) due to superior fundamental profitability (N/A vs. N/A operating margin) and revenue trajectory (N/A vs. N/A YoY). Technical & Structure Timing Caution: GAB is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.8); meanwhile GRX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
GAB leads the Growth & Scale pillar: GAB posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with GRX at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, GAB generates N/A in USD-normalized revenue versus N/A for GRX. In operating R&D and SG&A reinvestment, GAB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GRX.
GAB and GRX trade at balanced relative valuation multiples. GAB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas GRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GAB (N/A ROE) versus GRX (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, GAB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 19% Vol realized risk). By comparison, GRX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.14β · 14% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.